Overview

Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy

Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the opioid-sparing efficacy of parecoxib 40 mg intravenously given as a loading dose followed by 20 mg intravenously in the 24 hours after the end of surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Morphine
Parecoxib